Loading

Celine Biotechnologies

June 06, 2024
Session
Company Description: We are pioneering a novel approach by integrating proprietary synthetic biology methods and de novo protein designs with the power of generative AI to automate the discovery process and develop patient-tailored immune-mediated therapies at scale for Chronic and Age-Related diseases (tech-bio platform). Our platform has been validated across different case studies (in vitro, in vivo) including (T-Cell Engagers, CAR-T/NK), completed 2 pilot studies (4LOIs), 1 pilot confirmed with major pharma, part of Merck DSS, TMC for Cancer Therapeutics, Pear VC PFC, J&J with initial investments from some VCs.

Celine Biotechnologies
View all SUS 2024

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS